After Falling 21% in a Month, Is There Any Hope for BioCryst Pharmaceuticals?
After announcing a pause in clinical trial enrollment for its biggest pipeline program on April 8, BioCryst Pharmaceuticals (NASDAQ: BCRX) saw its shares take a nosedive that has left them down by more than 21% compared to a mere month ago. Though the rare disease biotech's base of revenue isn't directly affected by the pause, investors are likely concerned it might mean less income in the future.
In my view, the stampede away from BioCryst is a bit overblown. Follow along as I explore why I think that's the case.
Image source: Getty Images.
Source Fool.com
